Alaunos Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
This is an amended Schedule 13D/A filing by Robert W. Postma dated October 15, 2026, regarding beneficial ownership in Alaunos Therapeutics. The actual substantive changes to ownership positions, share counts, percentages, or counterparty details are not visible in the header/metadata provided; the filing document content itself is not disclosed in this submission.
Why this rating
Schedule 13D/A filings are routine disclosure amendments; significance depends entirely on ownership stakes and changes, which are not specified here. Without concrete numbers, this appears administrative.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.